Original document(12 pages) Authorized document(12 pages) 中文版
    The present invention is solid tumor treating medicine composition and belongs to the field of medicine technology. The medicine composition contains melphalan in effective anticancer amount and medicinal supplementary material. The medicinal supplementary material is mainly biocompatible, degradable and absorbable polymer, and during the degradation and absorption of the polymer, melphalan is released slowly to local tumor part to lower the systemic toxic reaction and to maintain local medicine concentration. The present invention has enhanced treating effect. The solid tumor includes cerebral tumor, liver cancer, lung cancer, esophagus cancer, gastric cancer, etc.
Application Number
申请号
200510043481 Application Date
申请日
2005.05.13
Title 名称 Solid tumor treating medicine composition
Publication Number
公开号
1706374 Publication Date
公开日
2005.12.14
Approval Pub. Date 2007.04.25 Granted Pub. Date 2007.04.25
International Classification 分类号 A61K31/198;A61K9/08;A61K9/10;A61K9/00;A61P35/00
Applicant(s) Name
申请人
Shandong Lanjin Bioengineering Co., Ltd.
Address 地址
Inventor(s) Name 发明人 Kong Qingzhong
Attorney & Agent 代理人 li baocheng

  
Anticarcinogen composition
Anticarcinogen composition
Anticarcinogen composition
Anticarcinogenic internal implant agent
Slow-release anticarcinogen contg. carmustine and fluorouracil
Anti-cancer medicine composition carried with platinum-like compounds and glucocorticoid hormone
Entity-tumor-resistant slow-release agent
Entity-tumor-resistant medicine composition
Anti-cancer composition containing glucocorticoid hormone
Anti-cancer slow-release agent carried with glucocorticoid hormone and chemical therapy medicine
Google
Note:All patent data come from State Intellectual Property Office of the People's Republic of China. If there were discrepancies between here and the State Intellectual Property office, the later is more accurate. The patent data is only for public exchange and learning purposes. We are not responsible for the adverse consequences with unverified use of the data.